% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • slumdawg2011 slumdawg2011 Nov 11, 2012 7:06 PM Flag


    From ECCO-org. EORTC-AACR meeting.

    Prof Petrylak and his colleagues from other US cancer centres recruited 50 patients to the phase I clinical trial. The patients had the most advanced form of prostate cancer, which had spread to the bone and other organs; they had failed hormone therapy and had received up to two previous chemotherapies. The researchers treated them with doses of PSMA ADC at levels ranging from 0.4 to 2.8 mg/kg, by intravenous infusion, over a period of three weeks per cycle, and for up to four treatment cycles.

    The researchers detected anti-tumour activity among the patients who were treated at the higher doses. About half of the patients who received doses of 1.8 mg/kg or more showed either a 50% or more reduction in PSA levels, or a fall in CTC in the blood to less than five cells per 7.5 ml of blood, or both.

    Anybody know how the results compare to MDVN drug?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The superiority of enzalutamide over placebo was shown with respect to all secondary end points: the proportion of patients with a reduction in the prostate-specific antigen (PSA) level by 50% or more (54% vs. 2%, P

      • 1 Reply to slumdawg2011
      • And finally:
        From ph1/2 of enzalutamide, 37% had CTC conversion from favorable to unfavorable.
        For JnJs abiraterone ph3, 34-41% had CTC conversion from favorable to unfavorable, while 36-51% had psa decline 50% at week 12.

        Based on placebo arm of enzalutamide ph3, it does look like PGNX's anti-PSMA ADC is demonstrating activity. It would be good to see the tables presented in the EORTC conference.

56.57+0.86(+1.54%)Sep 27 4:00 PMEDT